BACKGROUND: Recently, a "hybrid therapy" strategy has been used for successful rhythm control in persistent and permanent atrial fibrillation (AF) patients. The impact of this strategy on arrhythmia recurrences and subsequent AF related hospitalizations are unknown. MATERIALS AND METHODS: Forty-seven patients (66 +/- 10 years) with symptomatic persistent (N = 26) or permanent (N = 21) AF underwent "hybrid therapy" and were followed for 24 +/- 15 months. All patients underwent linear right atrial ablation and implantation of pacemaker or atrioventricular defibrillator (AVICD) capable of continuous right atrial pacing with previously ineffective antiarrhythmic drug therapy for AF prevention. Device data-logs were used to monitor AF recurrences. RESULTS: Freedom from permanent AF was 97, 90, and 83% at 6 months, 2 and 3 years, respectively. Sixteen patients (34%) had no recurrent AF after "hybrid therapy." Thirty-one patients (66%) had a total of 55 AF recurrences (mean 1.8 per patient). There was a significant reduction in the mean AF related hospitalizations (from 3.5 +/- 2.8 to 0.57 +/- 1.1 per patient), cardioversion hospitalizations (from 3.5 +/- 2.2 to 0.38 +/- 0.5 per patient) and DC cardioversions (from 3.1 +/- 3.9 to 0.7 +/- 0.5 per patient) after hybrid therapy compared to event rates before therapy (p < 0.05 for all). CONCLUSIONS: Rhythm control improves significantly with hybrid therapy in patients with persistent and permanent AF refractory to drugs and cardioversion therapy. This improvement is associated with a significant reduction in AF related hospitalizations and need for cardioversion therapy.
BACKGROUND: Recently, a "hybrid therapy" strategy has been used for successful rhythm control in persistent and permanent atrial fibrillation (AF) patients. The impact of this strategy on arrhythmia recurrences and subsequent AF related hospitalizations are unknown. MATERIALS AND METHODS: Forty-seven patients (66 +/- 10 years) with symptomatic persistent (N = 26) or permanent (N = 21) AF underwent "hybrid therapy" and were followed for 24 +/- 15 months. All patients underwent linear right atrial ablation and implantation of pacemaker or atrioventricular defibrillator (AVICD) capable of continuous right atrial pacing with previously ineffective antiarrhythmic drug therapy for AF prevention. Device data-logs were used to monitor AF recurrences. RESULTS: Freedom from permanent AF was 97, 90, and 83% at 6 months, 2 and 3 years, respectively. Sixteen patients (34%) had no recurrent AF after "hybrid therapy." Thirty-one patients (66%) had a total of 55 AF recurrences (mean 1.8 per patient). There was a significant reduction in the mean AF related hospitalizations (from 3.5 +/- 2.8 to 0.57 +/- 1.1 per patient), cardioversion hospitalizations (from 3.5 +/- 2.2 to 0.38 +/- 0.5 per patient) and DC cardioversions (from 3.1 +/- 3.9 to 0.7 +/- 0.5 per patient) after hybrid therapy compared to event rates before therapy (p < 0.05 for all). CONCLUSIONS: Rhythm control improves significantly with hybrid therapy in patients with persistent and permanent AF refractory to drugs and cardioversion therapy. This improvement is associated with a significant reduction in AF related hospitalizations and need for cardioversion therapy.
Authors: Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns Journal: N Engl J Med Date: 2002-12-05 Impact factor: 91.245
Authors: T Jared Bunch; Samuel J Asirvatham; Paul A Friedman; Kristi H Monahan; Thomas M Munger; Robert F Rea; Lawrence J Sinak; Douglas L Packer Journal: J Cardiovasc Electrophysiol Date: 2005-11
Authors: A K Bhandari; J L Anderson; E M Gilbert; B L Alpert; R W Henthorn; A L Waldo; M T Cullen; R W Hawkinson; E L Pritchett Journal: Am Heart J Date: 1992-08 Impact factor: 4.749
Authors: Mark D O'Neill; Pierre Jaïs; Yoshihide Takahashi; Anders Jönsson; Frédéric Sacher; Mélèze Hocini; Prashanthan Sanders; Thomas Rostock; Martin Rotter; Andrej Pernat; Jacques Clémenty; Michel Haïssaguerre Journal: J Interv Card Electrophysiol Date: 2006-11-14 Impact factor: 1.900
Authors: V Fuster; L E Rydén; R W Asinger; D S Cannom; H J Crijns; R L Frye; J L Halperin; G N Kay; W W Klein; S Lévy; R L McNamara; E N Prystowsky; L S Wann; D G Wyse; R J Gibbons; E M Antman; J S Alpert; D P Faxon; V Fuster; G Gregoratos; L F Hiratzka; A K Jacobs; R O Russell; S C Smith; W W Klein; A Alonso-Garcia; C Blomström-Lundqvist; G De Backer; M Flather; J Hradec; A Oto; A Parkhomenko; S Silber; A Torbicki Journal: J Am Coll Cardiol Date: 2001-10 Impact factor: 24.094
Authors: Richard L Page; Thomas W Tilsch; Stuart J Connolly; Daniel J Schnell; Stephen R Marcello; William E Wilkinson; Edward L C Pritchett Journal: Circulation Date: 2003-03-04 Impact factor: 29.690
Authors: G N Kay; K A Ellenbogen; M Giudici; M M Redfield; L S Jenkins; M Mianulli; B Wilkoff Journal: J Interv Card Electrophysiol Date: 1998-06 Impact factor: 1.900
Authors: Sanjeev Saksena; April Slee; Albert L Waldo; Nick Freemantle; Mathew Reynolds; Yves Rosenberg; Snehal Rathod; Shannon Grant; Elizabeth Thomas; D George Wyse Journal: J Am Coll Cardiol Date: 2011-11-01 Impact factor: 24.094